Why the study?
Does prostaglandin E1 infusion have safe and beneficial cardiopulmonary effects in patients with severe peripheral arterial occlusive disease?
Does prostaglandin E1 infusion have safe and beneficial cardiopulmonary effects in patients with severe peripheral arterial occlusive disease?
Prostaglandin E1 is an efficacious and safe treatment for severe peripheral arterial occlusive disease, offering favorable cardiopulmonary hemodynamic effects with a low incidence of adverse events.
Supports PGE1 hemodynamic benefits in severe PAOD; leaves open confirmation via randomized trials.
Intraarterial and intravenous infusion of prostaglandin E 1 (PGE 1 ) is established treatment for severe peripheral arterial occlusive disease, particularly in Europe and Japan. In this critical appraisal, experimental and clinical studies are reviewed, with special emphasis on cardiopulmonary effects and drug safety. The pulmonary data all indicate dose-dependent dilation of the pulmonary vessels with a reduction in pulmonary resistance. The known hemodynamic effects of PGE 1 on the heart include an increase in stroke volume, cardiac index, and left ventricular ejection fraction, and a reduction in left ventricular filling pressure. Analysis of clinical trials shows a low rate of adverse effects, in particular a low incidence of cardiopulmonary side effects. If the recommendations for high-risk patients are observed, PGE 1 is both an efficacious and safe therapeutic principle.
No takes yet. Share an insight, caveat, or question.
Heidrich et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: